Physician profile
Frank E Dickens
NPI 1225060858
$2,161.33
in general payments reported to CMS, 2019-2025
27 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $90.04 · 2021: $125 · 2022: $384 · 2023: $453 · 2024: $325 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.78 |
| Education | $268.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $266.87 | 2023-2024 | Ensite, Cardiomems |
| Gynesonics, INC. | $266.80 | 2022 | |
| Abbvie INC. | $199.40 | 2019-2023 | Oriahnn, Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $189.20 | 2019-2025 | Aptima, Acessa Provu System |
| Pfizer INC. | $182.87 | 2019-2024 | |
| Astellas Pharma US INC | $136.49 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $116.49 | 2022-2025 | |
| Coopersurgical, INC. | $95.62 | 2019-2024 | Endosee, Summit Doppler, Paragard T 380a |
| Exact Sciences Corporation | $81.61 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $79.70 | 2023-2025 | Myfembree, Gemtesa |
| Millicent US INC | $75.31 | 2019-2024 | |
| Exeltis, USA INC. | $72.86 | 2019-2024 | Slynd |
| Therapeuticsmd, INC. | $52.53 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $52.27 | 2019-2022 | |
| Duchesnay USA Incorporated | $39.77 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.49 | 2019-2020 | |
| Coloplast Corp | $34.82 | 2024 | |
| Lupin INC. | $32.67 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $30.04 | 2019 | |
| Shield Therapeutics INC | $24.48 | 2025 | |
| Organon LLC | $24.36 | 2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $22.01 | 2019-2021 | |
| Agile Therapeutics, INC. | $13.60 | 2021 | |
| Avion Pharmaceuticals | $12.78 | 2022 | |
| Scynexis, INC. | $11.74 | 2022 | |
| Intuitive Surgical, INC. | $9.55 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Dickens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.